J. Smyth

A. Rodger, U. Chetty, J. Smyth, 1991, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Inhibition of cell signalling pathways.

J. Smyth, S. Langdon, 1995, Cancer treatment reviews.

Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: an EORTC early clinical studies group investigation.

D. Dunlop, J. Smyth, T. Cerny, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Enzymology of mitomycin C metabolic activation in tumour tissue: implications for enzyme-directed bioreductive drug development.

M. Tomasz, J. Cummings, J. Smyth, 1998, Biochemical pharmacology.

Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall.

J. Smyth, S. Prescott, K. James, 1992, The Journal of urology.

Radio-immunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy.

J. Smyth, S. Prescott, K. James, 1990, The Journal of urology.

HLA-DR expression by high grade superficial bladder cancer treated with BCG.

J. Smyth, S. Prescott, K. James, 1989, British journal of urology.

Cellular heterogeneity and drug resistance in two ovarian adenocarcinoma cell lines derived from a single patient

C. Wolf, C. Wolf, J. Smyth, 1987, International journal of cancer.

Expression of interferon-γ receptors on bladder cancer cells: does it correlate with biological response?

J. Smyth, A. Jackson, K. James, 2004, Urological Research.

Growth control by epidermal growth factor and transforming growth factor-alpha in human lung squamous carcinoma cells.

J. Bartlett, J. Smyth, S. Langdon, 1992, British Journal of Cancer.

Determination of two neuropeptide growth factor antagonists, [D-Arg1,D-Phe5,D-Trp7,9,Leu11]-substance P and [Arg6,D-Trp7,9,N-MePhe8]- substance P(6-11), by high-performance liquid chromatography with electrochemical detection.

J. Smyth, S. Langdon, E. Rozengurt, 1994, Journal of chromatography. B, Biomedical applications.

Mitoxantrone for the treatment of advanced breast cancer: single-agent therapy in previously untreated patients.

H. Mouridsen, A. V. van Oosterom, I. Smith, 1984, European journal of cancer & clinical oncology.

Forearm blood flow and local responses to peptide vasodilators: a novel pharmacodynamic measure in the phase I trial of antagonist G, a neuropeptide growth factor antagonist.

J. Smyth, D. Jodrell, S. Clive, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

The inhibitory effects of interferon gamma on the growth of bladder cancer cells.

J. Smyth, S. Prescott, A. Jackson, 1992, The Journal of urology.

Transforming growth factor-beta mRNA expression and growth control of human ovarian carcinoma cells.

J. Bartlett, J. Smyth, S. Langdon, 1992, British Journal of Cancer.

Studying lung cancer in the laboratory: 3--Use of cell lines to investigate the biology of lung cancer.

J. Smyth, R. Fergusson, 1987, Thorax.

Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron?

M. Nicolson, J. Smyth, R. Coleman, 1991, BMJ.

Effective dosing of topotecan with carboplatin in relapsed ovarian cancer: a phase I/II study.

J. Smyth, T. Rye, G. Ross, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of sodium butyrate and other differentiation inducers on poorly differentiated human ovarian adenocarcinoma cell lines.

J. Smyth, S. Langdon, S. Lawrie, 1988, Cancer research.

Phase I study of intraperitoneal metalloproteinase inhibitor BB94 in patients with malignant ascites.

J. Smyth, G. Beattie, Gerald J. Beattie, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

PROGNOSTIC FACTORS IN ADVANCED NON-SEMINOMATOUS GERM-CELL TESTICULAR TUMOURS: RESULTS OF A MULTICENTRE STUDY Report from the Medical Research Council Working Party on Testicular Tumours

K. Sikora, A. Horwich, P. Wilkinson, 1985, The Lancet.

Activity of the dolastatin analogue, LU103793, in malignant melanoma.

J. Wanders, J. Smyth, H. Calvert, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly.

J. Smyth, D. Jodrell, A. Bernareggi, 2000, European journal of cancer.

The homeobox gene BARX2 can modulate cisplatin sensitivity in human epithelial ovarian cancer.

D. Porteous, H. Gabra, J. Smyth, 2002, International journal of oncology.

In vivo toxicity to lymphoid tissue by 2′-Deoxycoformycin

J. Smyth, R. Young, D. Young, 2004, Cancer Chemotherapy and Pharmacology.

Association of galectin-3 expression with melanoma progression and prognosis.

J. Bartlett, D. Melton, J. Smyth, 2012, European journal of cancer.

Functionality of the progesterone receptor in ovarian cancer and its regulation by estrogen.

H. Gabra, J. Bartlett, J. Smyth, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Doxorubicin‐loaded Casein Microspheres: Protean Nature of Drug Incorporation

J. Cummings, J. Smyth, G. Halbert, 1992, The Journal of pharmacy and pharmacology.

Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation.

J. S. Macpherson, J. Cummings, J. Smyth, 2002, Biochemical pharmacology.

Factors influencing the cellular accumulation of SN-38 and camptothecin

Gillian Smith, J. S. Macpherson, J. Cummings, 2002, Cancer Chemotherapy and Pharmacology.

Phase I study of the novel anticancer drug PM00104 as a 24-hour IV infusion every 3 weeks (q3w) in patients (pts) with advanced solid tumors or lymphoma.

J. Baselga, J. Tabernero, J. Smyth, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumor size, response rate, and prognosis in small cell carcinoma of the bronchus treated by combination chemotherapy.

R. Souhami, J. Smyth, F. Fearon, 1982, Cancer treatment reports.

Higher Incidence of Isolated Brain Metastases in Ovarian Cancer Patients With Previous Early Breast Cancer

J. Smyth, D. Faratian, C. Gourley, 2010, International Journal of Gynecologic Cancer.

Determination of the glucuronide metabolites of the topoisomerase I inhibitors 7-Ethyl 10-hydroxycamptothecin (SN-38) and NU/ICRF 505 by high-performance liquid chromatography

J. Cummings, J. Smyth, D. Jodrell, 2002 .

Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group.

J. Wanders, J. Verweij, C. Sessa, 1994, British Journal of Cancer.

Early mortality rates: a tool for phase III trials or for changing standard practice?

J. Verweij, J. Smyth, 2004, European Journal of Cancer.

Cis-platin and methotrexate in the treatment of transitional cell carcinoma of the urinary tract.

J. Carmichael, J. Smyth, G. Chisholm, 1985, British journal of urology.

Endometrioid epithelial ovarian cancer

H. Gabra, J. Smyth, T. Rye, 2008, Cancer.

Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC.

J. Wanders, P. Schőffski, C. Sessa, 1994, European journal of cancer.

The long-term retention of platinum in human tissues following the administration of cisplatin or carboplatin for cancer chemotherapy.

P. Tothill, J. Smyth, H. Klys, 1992, European journal of cancer.

Bowel obstruction in ovarian carcinoma: a retrospective study and review of the literature

J. Smyth, R. Leonard, G. Beattie, 1989 .

Inhibition of transforming growth factor α (TGF-α)-mediated growth effects in ovarian cancer cell lines by a tyrosine kinase inhibitor ZM 252868

J. Bartlett, J. Smyth, S. Langdon, 1999, British Journal of Cancer.

Guidelines for the use of Intron A (interferon alfa-2b) in clinical oncology: lessons from the laboratory.

J. Smyth, 1988, Cancer treatment reviews.

A human tumor model

U. Chetty, A. Forrest, J. Smyth, 1986 .

Malignant mixed mesodermal tumours: biology and clinical aspects.

H. Gabra, J. Smyth, C. Gourley, 2002, European journal of cancer.

Carcinosarcoma of the ovary

H. Gabra, M. Bradburn, J. Smyth, 2004, Cancer.

Estrogen and Anti‐Estrogen Effects on the Growth of Human Epithelial Ovarian Cancer In Vitro

R. Ozols, J. Smyth, T. Hamilton, 1989, Obstetrics and gynecology.

Contrasting effects of 17 β‐estradiol on the growth of human ovarian carcinoma cells in vitro and in vivo

J. Smyth, S. Langdon, W. Miller, 1993 .

Emesis due to cancer chemotherapy: results of a prospective, randomised, double-blind trial of varying doses of metoclopramide in the management of cis-platinum-induced vomiting.

J. Smyth, R. Leonard, M. Cornbleet, 1984, European journal of cancer & clinical oncology.

The metabolism of cytosine arabinoside as a predictive test for clinical response to the drug in acute myeloid leukaemia.

J. Smyth, A. Robins, C. Leese, 1976, European journal of cancer.

Corticosteroids, dopamine antagonists and other drugs

A. Favero, M. Aapro, J. Smyth, 1998, Supportive Care in Cancer.

Treatment of advanced breast cancer with the aromatase inhibitor 4-hydroxyandrostenedione: a phase II trial

M. Dowsett, A. Rodger, A. Forrest, 1994 .

Pharmacology of adriamycin: the message to the clinician.

J. Cummings, J. Smyth, 1988, European journal of cancer & clinical oncology.

cis-Platinum and vindesine in combination in the treatment of non-small cell lung cancer.

A. Gregor, J. Carmichael, J. Smyth, 1985, European journal of cancer & clinical oncology.

The EORTC Early Clinical Trials Cooperative Group experience with 5-aza-2'-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas.

M. van Glabbeke, M. Glabbeke, J. Smyth, 1987, European journal of cancer & clinical oncology.

Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial

P. Dziewulski, M. Gore, M. Highley, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

MALIGNANT MELANOMA IN SCOTLAND 1979-1983

K. Calman, J. Hunter, R. MacKie, 1985, The Lancet.

Characterization of the major metabolites of flavone acetic acid and comparison of their disposition in humans and mice.

D. Kerr, J. Double, M. Bibby, 1989, Cancer research.

Role of adenosine deaminase in lymphocyte proliferation.

J. Smyth, S. Williams, T. Hovi, 1976, Clinical and experimental immunology.

Experimental cerebral and plasma pharmacokinetic studies of TCNU: implications for brain tumour chemotherapy.

J. Miller, I. Whittle, J. S. Macpherson, 1987, British journal of neurosurgery.

Biochemistry of topoisomerase I and II inhibition by anthracenyl-amino acid conjugates.

J. S. Macpherson, J. Cummings, J. Smyth, 1995, Biochemical pharmacology.

Processing of [d-Arg1,d-Phe5,d-Trp7,9,Leu11]Substance P in Xenograft Bearing Nu/Nu Mice

J. Smyth, S. Langdon, A. Ritchie, 1997, Peptides.

The clinical pharmacology of the adenosine deaminase inhibitor 2′-deoxycoformycin

R. Adamson, J. Smyth, A. Jackman, 2004, Cancer Chemotherapy and Pharmacology.

Biochemical consequences of treatment with the adenosine deaminase inhibitor 2'-deoxycoformycin.

J. Smyth, K. Harrap, R. Paine, 1979, Advances in experimental medicine and biology.

Docetaxel (Taxotere), a novel taxoid, in the treatment of advanced colorectal carcinoma: an EORTC Early Clinical Trials Group Study.

C. Sternberg, N. Pavlidis, S. Kaye, 1994, British Journal of Cancer.

Growth-inhibitory effects of the synthetic retinoid CD437 against ovarian carcinoma models in vitro and in vivo

U. Reichert, J. Smyth, S. Langdon, 1998, Cancer Chemotherapy and Pharmacology.

The human tumour xenograft—a valid model in experimental chemotherapy?

A. Shorthouse, J. Smyth, G. Steel, 1980, The British journal of surgery.

BARX2 induces cadherin 6 expression and is a functional suppressor of ovarian cancer progression.

D. Porteous, H. Gabra, J. Smyth, 2001, Cancer research.

Processing of the neuropeptide growth factor antagonist [Arg6, D-Trp7.9, NmePhe8]-substance P (6-11) by a small cell lung cancer cell line (H69).

J. Smyth, S. Langdon, E. Rozengurt, 1995, Biochemical pharmacology.

The consequences of doxorubicin quinone reduction in vivo in tumour tissue.

J. Cummings, J. Smyth, J. F. Smyth, 1992, Biochemical pharmacology.

Clinically relevant fatigue in recurrence-free prostate cancer survivors.

M. Sharpe, J. Smyth, D. McLaren, 2012 .

Determination of reactive nitrogen mustard anticancer drugs in plasma by high-performance liquid chromatography using derivatization.

J. Cummings, J. Smyth, P. Farmer, 1991, Analytical chemistry.

Definition and refinement of a region of loss of heterozygosity at 11q23.3-q24.3 in epithelial ovarian cancer associated with poor prognosis.

D. Porteous, H. Gabra, J. Smyth, 1996, Cancer research.

Induction of apoptosis in human cancer cell lines by the novel anthracenyl-amino acid topoisomerase I inhibitor NU/ICRF 505.

J. S. Macpherson, J. Cummings, J. Smyth, 1996, British Journal of Cancer.

Cytogenetic evaluation of the mechanism of cell death induced by the novel anthracenyl-amino acid topoisomerase II catalytic inhibitor NU/ICRF 500.

J. S. Macpherson, J. Cummings, J. Smyth, 1995, Mutation research.

Pharmacological determinants of the antitumour activity of mitomycin C.

J. Cummings, J. Smyth, V. Spanswick, 1998, Biochemical pharmacology.

Current status of research into small cell carcinoma of the lung: summary of the Second Workshop of the International Association for the Study of Lung Cancer (IASLC).

H. Hansen, J. Smyth, 1985, European journal of cancer & clinical oncology.

Failure of intensive combination therapy (cyclophosphamide, adriamycin, 5-fluorouracil) to control adenocarcinoma or large-cell anaplastic carcinoma of lung

I. Smith, J. Smyth, H. Ford, 2004, Cancer Chemotherapy and Pharmacology.

Determination of the novel topoisomerase I inhibitor NU/ICRF 505 and its major metabolite in plasma, tissue and tumour by high-performance liquid chromatography.

J. S. Macpherson, J. Cummings, J. Smyth, 1996, Journal of chromatography. B, Biomedical applications.

How to improve the cost effectiveness of oncology drug development A commentary on Tan et al. Anti-cancer drug resistance--understanding the mechanisms through the use of integrative genomics and functional RNA interference.

J. Smyth, C. McCabe, 2010, European journal of cancer.

Paraneoplastic hypercalcaemia in ovarian carcinoma.

J. Smyth, R. Leonard, S. Allan, 1984, British medical journal.

Prognostic factors forsurvival insoft tissue sarcoma

G. Kerr, A. Rodger, J. Smyth, 1990 .

Flavone 8-acetic acid: our current understanding of its mechanism of action in solid tumours

J. Cummings, J. Smyth, 2004, Cancer Chemotherapy and Pharmacology.

THERAPEUTIC SELECTIVITY OF AND PREDICTION OF RESPONSE TO 2'-DEOXYCOFORMYCIN IN ACUTE LEUKAEMIA

A. Piga, J. Smyth, N. Russell, 1981, The Lancet.

Adenosine deaminase activity in leukaemia.

J. Smyth, K. Harrap, 1975, British Journal of Cancer.

High-dose alkylating agent therapy: a review of clinical experiences.

J. Smyth, R. Leonard, M. Cornbleet, 1984, Cancer drug delivery.

Inductively coupled plasma mass spectrometry for the determination of platinum in animal tissues and a comparison with atomic absorption spectrometry

P. Tothill, J. Smyth, L. M. Matheson, 1990 .

Enhanced DNA repair and resistance to cisplatin in human ovarian cancer.

R. Ozols, J. Smyth, G. Lai, 1988, Biochemical pharmacology.

DNA topoisomerase I and II as targets for rational design of new anticancer drugs.

J. Cummings, J. Smyth, Jeffrey Cummings, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

REMISSION INDUCTION WITH ADENOSINE-DEAMINASE INHIBITOR 2'-DEOXYCOFORMYCIN IN THY-LYMPHOBLASTIC LEUKÆMIA

G. Janossy, J. Smyth, K. Ganeshaguru, 1980, The Lancet.

Hemolysis and erythropoiesis. IV. Effect of hemolysates on the erythropoiesis of normal, starved, and polycythemic rats.

J. Smyth, J. Labardini, L. Sánchez-Medal, 1968, The Journal of laboratory and clinical medicine.

Identification of anthracenyl-dipeptide conjugates as novel topoisomerase I and II inhibitors and their evaluation as potential anticancer drugs.

J. S. Macpherson, J. Cummings, J. Smyth, 1995, Anti-cancer drug design.

Characterization and properties of nine human ovarian adenocarcinoma cell lines.

J. Smyth, S. Langdon, S. Lawrie, 1988, Cancer research.

The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans.

George Kollias, John F Smyth, Toby Lawrence, 2009, The Journal of clinical investigation.

Antisense Oligonucleotide Targeting of Raf-1

B. Monia, J. Smyth, P. Mullen, 2004, Clinical Cancer Research.

Mucosal melanomas of the head and neck: The Scottish experience. The Scottish Melanoma Group.

G. Kerr, M. Gaze, J. Smyth, 1990, Clinical oncology (Royal College of Radiologists (Great Britain)).

Optimization of the Stability of [Arg6, D‐Trp7,9, NmePhe8]‐Substance P (6–11) For Continuous Infusion to Cancer Patients

J. Smyth, D. A. Jones, J. Cummings, 2011 .

Stability and in vitro metabolism of the mitogenic neuropeptide antagonists [D-Arg1,D-Phe5, D-Trp7,9, Leu11]-substance P and [Arg6, D-Trp7,9, MePhe8]-substance P (6-11) characterized by high-performance liquid chromatography.

J. Smyth, S. Langdon, J. Cummings, 1994, Journal of pharmaceutical and biomedical analysis.

Determination of mitomycin C, 2,7-diaminomitosene, 1,2-cis- and 1,2-trans-1-hydroxy-2,7-diaminomitosene in tumour tissue by high-performance liquid chromatography.

J. Cummings, J. Smyth, G. Halbert, 1993, Journal of Chromatography A.

Deoxycoformycin in the Treatment of Leukemias and Lymphomas a

J. Smyth, A. Hoffbrand, H. G. Prentice, 1985, Annals of the New York Academy of Sciences.

Biochemical determinants for antileukemia drug treatment.

J. Smyth, 1979, Haematology and blood transfusion.

The disposition of TCNU (tauromustine) in human malignant glioma: pharmacokinetic studies and clinical implications.

J. Miller, I. Whittle, J. S. Macpherson, 1990, Journal of neurosurgery.

Enzymology of mitomycin C metabolic activation in tumour tissue. Characterization of a novel mitochondrial reductase.

J. Cummings, J. Smyth, V. Spanswick, 1996, Biochemical pharmacology.

Re-evaluation of the molecular pharmacology of mitomycin C.

J. Cummings, J. Smyth, V. Spanswick, 1995, European journal of cancer.

Conversion of mitomycin C to 2,7-diaminomitosene and 10-decarbamoyl 2,7-diaminomitosene in tumour tissue in vivo

J. Cummings, J. Smyth, G. Halbert, 1995, Cancer Chemotherapy and Pharmacology.

Current issues in the enzymology of mitomycin C metabolic activation.

J. Cummings, J. Smyth, V. Spanswick, 1998, General pharmacology.

Encapsulation of mitomycin C in albumin microspheres markedly alters pharmacokinetics, drug quinone reduction in tumour tissue and antitumour activity. Implications for the drugs' in vivo mechanism of action.

J. Cummings, J. Smyth, L. Allan, 1994, Biochemical pharmacology.

Incorporation and release of chemically intact mitomycin C from albumin microspheres: a high performance liquid chromatography evaluation.

J. Cummings, J. Smyth, N. Willmott, 1993, Journal of drug targeting.

Application of high-performance liquid chromatography for recognition of covalent nucleic acid modification with anticancer drugs.

J. Cummings, J. Smyth, R. French, 1993, Journal of chromatography.

Studies on the Biochemical Sequelae of Therapy in Thy‐Acute Lymphoblastic Leukaemia with the Adenosine Deaminase Inhibitor 2’Deoxycoformycin

A. Piga, J. Smyth, K. Ganeshaguru, 1981, British journal of haematology.

A 700-kb physical map of a region of 16q23.2 homozygously deleted in multiple cancers and spanning the common fragile site FRA16D.

J. Sgouros, A. Stewart, D. Porteous, 2000, Cancer research.

Identification of a region of frequent loss of heterozygosity at 11q24 in colorectal cancer.

H. Gabra, A. Wyllie, J. Smyth, 1999, Cancer research.

Glutathione reduces the toxicity and improves quality of life of women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial.

R. Prescott, P. Wilkinson, J. Smyth, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Chromosome 11 allele imbalance and clinicopathological correlates in ovarian tumours.

D. Eccles, H. Gabra, J. Smyth, 1995, British Journal of Cancer.

Identification of clinically relevant genes on chromosome 11 in a functional model of ovarian cancer tumor suppression.

Cherie Blenkiron, John F Smyth, Euan A Stronach, 2003, Cancer research.

WWOX: A candidate tumor suppressor gene involved in multiple tumor types

D J Porteous, D. Porteous, A. Paige, 2001, Proceedings of the National Academy of Sciences of the United States of America.

Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity.

R. L. Hayward, J. S. Macpherson, J. Cummings, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

The Anti-proliferative Activity of Interferon-γ on Ovarian Cancer: In Vitro and in Vivo

F. Balkwill, J. Smyth, L. Wall, 2003 .

Randomized phase II trial of TCNU versus mitozolomide in malignant melanoma

J. Smyth, S. Gundersen, H. Pinedo, 1989 .

WWOX tumour suppressor gene polymorphisms and ovarian cancer pathology and prognosis.

S. Richardson, Robert Brown, T. Ganesan, 2010, European journal of cancer.

WWOX gene expression abolishes ovarian cancer tumorigenicity in vivo and decreases attachment to fibronectin via integrin alpha3.

A. Paige, H. Gabra, C. Ward, 2009, Cancer research.

WWOX mRNA expression profile in epithelial ovarian cancer supports the role of WWOX variant 1 as a tumour suppressor, although the role of variant 4 remains unclear.

A. Paige, H. Gabra, J. Smyth, 2005, International journal of oncology.

Current research and treatment for epithelial ovarian cancer. A Position Paper from the Helene Harris Memorial Trust.

G. Mills, R. Bast, M. Gore, 2003, European journal of cancer.

Intensive investigation in management of Hodgkin's disease.

A. Stansfeld, P. Wrigley, J. Smyth, 1976, British medical journal.

The molecular pharmacology of doxorubicin in vivo.

J. Cummings, J. Smyth, N. Willmott, 1991, European journal of cancer.

The heterogeneity of human cancers and its influence on metastases and therapy.

J. Smyth, R. Leonard, 1985, European journal of cancer & clinical oncology.

Insulin-like Growth Factor Binding Proteins IGFBP3, IGFBP4, and IGFBP5 Predict Endocrine Responsiveness in Patients with Ovarian Cancer

John F Smyth, D. Cameron, J. Smyth, 2007, Clinical Cancer Research.

Insulin-like Growth Factor Binding Proteins IGFBP 3 , IGFBP 4 , and IGFBP 5 Predict Endocrine Responsiveness in Patients with Ovarian Cancer

D. Cameron, J. Smyth, S. Langdon, 2007 .

Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer.

D. Cameron, J. Smyth, S. Langdon, 2007, Gynecologic oncology.

Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling

D. Cameron, J. Smyth, P. Mullen, 2007, Molecular Cancer Therapeutics.

Editorial comment on 'A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy' by Schmitt et al.

R. L. Hayward, J. Smyth, 2002, European journal of cancer.

OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer

P. Bates, H. Gabra, B. Contreras-Moreira, 2003, Nature Genetics.

Glucuronidation as a mechanism of intrinsic drug resistance in human colon cancer: reversal of resistance by food additives.

Jeffrey Cummings, John F Smyth, J. S. Macpherson, 2003, Cancer research.

Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer.

N. Bleehen, R. Osborne, J. Smyth, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of human recombinant interferon-alpha on the activity of cis-diamminedichloroplatinum(II) in human non-small cell lung cancer xenografts.

J. Cummings, J. Smyth, A. Ritchie, 1995, Cancer investigation.

Original article: Potentiation of cisplatin by alpha-Interferon in advanced non-small cell lung cancer (NSCLC): A phase II study

A. Gregor, J. Smyth, G. Crompton, 1990 .

The use of real-world data in cancer drug development.

E. Skovlund, J. Smyth, H. Leufkens, 2018, European journal of cancer.

ELECTROCARDIOGRAPHIC MODIFICATIONS IN ANEMIA.

J. Smyth, L. Sánchez Medal, A. González de Cossío, 1964, American heart journal.

Protective effect of sodium-2-mercaptoethanesulfonate on the gastrointestinal toxicity and lethality of cis-diamminedichloroplatinum.

C. Wolf, J. Smyth, R. Leonard, 1986, Cancer research.

Small intestinal mucosal toxicity of cis-platinum--comparison of toxicity with platinum analogues and dexamethasone.

J. Smyth, S. Allan, 1986, British Journal of Cancer.

Quantification by gas chromatography of N,N'-di-(2-chloroethyl)-phosphorodiamidic acid in the plasma of patients receiving isophosphamide.

M. H. Baker, I. Smith, J. Smyth, 1980, Cancer research.

Deoxyribonucleoside triphosphate pools and adenosine toxicity.

J. Smyth, K. Harrap, 1977, Biochemical pharmacology.

Estrogen receptor-alpha mediates gene expression changes and growth response in ovarian cancer cells exposed to estrogen.

D. Burns, J. Smyth, S. Langdon, 2005, Endocrine-related cancer.

The IgLON Family in Epithelial Ovarian Cancer: Expression Profiles and Clinicopathologic Correlates

H. Gabra, J. Smyth, D. Scott, 2005, Clinical Cancer Research.

Relationship between reductive drug metabolism in tumour tissue of anthracyclines in microspherical form and anti-tumour activity.

J. Cummings, J. Smyth, N. Willmott, 1990, Biochemical Pharmacology.

Chapter 2 – Cytotoxic drug delivery

J. Cummings, J. Smyth, 1993 .

Correlation between tumour drug disposition and the antitumour activity of doxorubicin-loaded microspheres: implications for the drugs' in vivo mechanism of action.

J. Cummings, J. Smyth, N. Willmott, 1993, Biochemical pharmacology.

Covalent coupling of doxorubicin in protein microspheres is a major determinant of tumour drug disposition.

J. Cummings, J. Smyth, N. Willmott, 1991, Biochemical pharmacology.

Determination of covalent binding to intact DNA, RNA, and oligonucleotides by intercalating anticancer drugs using high-performance liquid chromatography. Studies with doxorubicin and NADPH cytochrome P-450 reductase.

A. Bartoszek, J. Cummings, J. Smyth, 1991, Analytical biochemistry.

Development of anthracenyl-amino acid conjugates as topoisomerase I and II inhibitors that circumvent drug resistance.

J. S. Macpherson, J. Cummings, J. Smyth, 1996, Biochemical pharmacology.

Loss of heterozygosity at 11q22 correlates with low progesterone receptor content in epithelial ovarian cancer.

H. Gabra, J. Smyth, S. Langdon, 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

Transforming growth factor-P mRNA expression andgrowth control of humanovarian carcinoma cells

J. Bartlett, J. Smyth, S. Langdon, 1992 .

Transforming growth factor-mRNA expression and growth control of human ovarian carcinoma cells

J. Bartlett, J. Smyth, S. Langdon, 2007 .

Management of small cell cancer: intensive chemotherapy.

A. Gregor, J. Smyth, 1984, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Hormone therapy for epithelial ovarian cancer

John F Smyth, J. Smyth, S. Langdon, 2008, Current opinion in oncology.

IFN-γ Induces Apoptosis in Ovarian Cancer Cells in Vivo and in Vitro

F. Balkwill, J. Smyth, L. Wall, 2003 .

IFN-gamma induces apoptosis in ovarian cancer cells in vivo and in vitro.

F. Balkwill, J. Smyth, L. Wall, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Evaluation of a novel heterologous PrimeBoost immunotherapy in stage III/IV metastatic melanoma patients

D. Schadendorf, A. Harris, J. Smyth, 2005 .

Expression of the Heat Shock Protein H5P27 in Human Ovarian Cancer

J. Smyth, S. Langdon, W. Miller, 1995 .

5-Aza-2'-deoxycytidine (NSC 127716) in non-seminomatous testicular cancer. Phase II from the EORTC Early Clinical Trials Cooperative Group and Genito-Urinary Group.

S. Fosså, S. Monfardini, S. Kaye, 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I study of methylacetylenic putrescine, an inhibitor of polyamine biosynthesis

J. Smyth, K. Haegele, A. Kingsnorth, 2004, Cancer Chemotherapy and Pharmacology.

Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer.

D. Kerr, T. Powles, G. Rustin, 1992, Oncology.

The clinical pharmacology of mitozantrone

C. Wolf, J. S. Macpherson, J. Smyth, 2004, Cancer Chemotherapy and Pharmacology.

Methotrexate in the chemotherapy of lung cancer.

J. Smyth, H. Ford, 1981, Cancer treatment reports.

Studying lung cancer in the laboratory--2: Chemosensitivity testing.

J. Smyth, J. Smyth, R. Fergusson, 1987, Thorax.

Studying lung cancer in the laboratory: 1--Development of model systems.

J. Smyth, R. Fergusson, 1987, Thorax.

Cardiotoxicity of mitozantrone assessed by stress and resting nuclear ventriculography.

J. Smyth, M. Merrick, J F Smyth, 1988, European journal of cancer & clinical oncology.

Optimum anti-emetic therapy for cisplatin induced emesis over repeat courses: ondansetron plus dexamethasone compared with metoclopramide, dexamethasone plus lorazepam.

J. Verweij, D. Cunningham, J. Smyth, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

New directions for anti-emetic research.

J. Smyth, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

High-performance liquid chromatographic technique for the simultaneous determination of lactone and hydroxy acid forms of camptothecin and SN-38 in tissue culture media and cancer cells.

J. Cummings, J. Smyth, D. Jodrell, 2001, Analytical biochemistry.

Cell cycle effects of the novel topoisomerase I inhibitor NU/ICRF 505 in a panel of Chinese hamster ovary cell lines.

J. S. Macpherson, J. Cummings, J. Smyth, 1997, European journal of cancer.

The Effect of Interferon-Alpha on the Activity of Cytotoxic Drugs in Bronchial Carcinoma Xenografts

J. Smyth, R. Fergusson, 1988 .

DYSTONIC REACTIONS DUE TO METOCLOPRAMIDE

J. Smyth, R. Leonard, M. Cornbleet, 1984, The Lancet.

The enzymology of doxorubicin quinone reduction in tumour tissue.

P. Workman, J. Cummings, J. Smyth, 1992, Biochemical pharmacology.

Studies on the molecular pharmacology of GR63178A. A novel pentacyclic pyrolloquinone anticancer drug.

I. Hickson, J. Cummings, J. Smyth, 1992, Biochemical pharmacology.

Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine

D. Schadendorf, A. Harris, P. Lorigan, 2010, Cancer Immunology, Immunotherapy.

Clinically relevant fatigue in recurrence-free prostate cancer survivors.

M. Sharpe, J. Smyth, D. McLaren, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Gemcitabine in patients with advanced malignant melanoma or gastric cancer: phase II studies of the EORTC Early Clinical Trials Group.

S. Aamdal, J. Wanders, C. Sessa, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer.

J. Smyth, P. Mullen, S. Langdon, 2005, Cancer research.

Cisplatin-Resistant Ovarian Cancer Altered ErbB Receptor Signaling and Gene Expression in

J. Smyth, P. Mullen, S. Langdon, 2005 .

A prognostic model for ovarian cancer

D G Altman, D. Altman, H. Gabra, 2001, British Journal of Cancer.

Interferon Alpha-2: Pre-Clinical and Clinical Evaluation

J. Smyth, D. Kisner, 2011, Developments in Oncology.

Augmentation of cytotoxicity of chemotherapy by human alpha-interferons in human non-small cell lung cancer xenografts.

J. Carmichael, F. Balkwill, C. Wolf, 1986, Cancer research.

Expression of the heat shock protein HSP27 in human ovarian cancer.

J. Smyth, S. Langdon, W. Miller, 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

Actual developments in European regulatory and health technology assessment of new cancer drugs: what does this mean for oncology in Europe?

K. Broich, S. Marsoni, H. Zwierzina, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Interferons in Oncology

J. Smyth, 1987, ESO Monographs.

The therapeutic response of bronchial carcinoma xenografts: a direct patient-xenograft comparison.

A. Shorthouse, J. Smyth, G. Steel, 1980, The British journal of cancer. Supplement.

PREPARATION OF IMMUNOSUPPRESSED MICE

J. Carmichael, J. Smyth, R. Fergusson, 2004 .

Activity of a new nitrosourea (TCNU) in human lung cancer xenografts.

P. Robins, J. S. Macpherson, J. Smyth, 1988, British Journal of Cancer.

Human tumour xenografts growing in immunodeficient mice: a useful model for assessing chemotherapeutic agents in bronchial carcinoma.

J. Carmichael, J. Smyth, R. Fergusson, 1986, Thorax.

Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer

B. Monia, J. Smyth, P. Mullen, 2001 .

Phase I study of TCNU, a novel nitrosourea.

J. S. Macpherson, J. Smyth, R. Leonard, 1987, European journal of cancer & clinical oncology.

The late results of consolidation treatment following induction chemotherapy for small cell lung cancer

A. Gregor, J. Smyth, R. Coleman, 1991 .

Optimising antiemesis in cancer chemotherapy: efficacy of continuous versus intermittent infusion of high dose metoclopramide in emesis induced by cisplatin.

J. S. Macpherson, J. Smyth, R. Leonard, 1986, British medical journal.

SMALL-CELL LUNG CANCER AFTER RETINOBLASTOMA

A. Gregor, J. Smyth, R. Leonard, 1988, The Lancet.

Can long-term survival be improved in patients with small-cell lung cancer (SCLC) and good performance status? Medical Research Council Lung Cancer Working Party.

R. Stephens, A. Gregor, D. Machin, 1994, British Journal of Cancer.

A Medical Research Council phase II trial of alternating chemotherapy and radiotherapy in small-cell lung cancer. The Medical Research Council Lung Cancer Working Party.

R. Stephens, A. Gregor, D. Machin, 1991, British Journal of Cancer.

The role of thoracic radiation therapy in small cell carcinoma of the lung: a concensus report

G. Giaccone, R. Arriagada, P. Dombernowsky, 1989 .

Molecular modeling of the interaction of anthracenyl-amino acid topoisomerase inhibitors with the DNA sequence d(CGTACG)

J. Cummings, J. Smyth, A. McGown, 1996, Anti-cancer drugs.

Phase I Clinical and Pharmacokinetic Study of Plitidepsin as a 1-Hour Weekly Intravenous Infusion in Patients with Advanced Solid Tumors

J. Smyth, D. Jodrell, J. Jimeno, 2008, Clinical Cancer Research.

A HUMAN TUMOUR MODEL

U. Chetty, A. Forrest, J. Smyth, 1986, The Lancet.

Prognosis at presentation of small cell carcinoma of the lung.

S. Love, J. Smyth, R. Leonard, 1990, European journal of cancer.

The Long Term Stability of Mechlorethamine Hydrochloride (Nitrogen Mustard) Ointment Measured by HPLC

J. Smyth, J. Cummings, A. MacLellan, 1993, The Journal of pharmacy and pharmacology.

Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours.

J. Wanders, J. Beijnen, J. Smyth, 2003, European journal of cancer.

Randomized phase II trial of iproplatin and carboplatin in advanced breast cancer

S. Kaye, J. Smyth, S. Gundersen, 1993 .

Pharmacological and biochemical determinants of the antitumour activity of the indoloquinone EO9.

J. Cummings, J. Smyth, V. Spanswick, 1998, Biochemical pharmacology.

Phase I study of the anthrapyrazole biantrazole: clinical results and pharmacology

S. Kaye, J. Cummings, J. Smyth, 2004, Cancer Chemotherapy and Pharmacology.

The comparative disposition of the pyrolloquinone GR63178A and its 9-hydroxy metabolite GR54374X in sensitive and resistant mouse colon adenocarcinoma

J. S. Macpherson, J. Cummings, J. Smyth, 2004, Cancer Chemotherapy and Pharmacology.

Chromatographic characterisation of six human metabolites of the new anticancer drug GR63 178A

J. Cummings, J. Smyth, A. MacLellan, 2004, Cancer Chemotherapy and Pharmacology.

Stability of GR63178A, a Novel Pentacyclic Pyrroloquinone Anticancer Compound, in Aqueous Solutions and Biological Fluids

J. Cummings, J. Smyth, R. French, 1993, The Journal of pharmacy and pharmacology.

Paracrine regulation of ovarian cancer by endothelin.

J. Smyth, S. Langdon, W. Miller, 1999, European journal of cancer.

The effects of recombinant human interferon-gamma on a panel of human bladder cancer cell lines.

J. Smyth, S. Prescott, A. Jackson, 1991, The Journal of urology.

INTERFERONS IN CANCER THERAPY: A REAPPRAISAL

F. Balkwill, J. Smyth, 1987, The Lancet.

Neuregulin expression, function, and signaling in human ovarian cancer cells.

J. Smyth, W. Gullick, S. Langdon, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Mitoxantrone versus doxorubicin in combination chemotherapy for advanced carcinoma of the breast.

S. Kaye, J. Smyth, R. Leonard, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mitozantrone and prednimustine in the treatment of advanced breast cancer — a toxic regimen with low activity

D. Eccles, A. Rodger, U. Chetty, 2004, Cancer Chemotherapy and Pharmacology.

Randomised trial comparing prednimustine with combination chemotherapy in advanced ovarian carcinoma

G. Kerr, J. Smyth, R. Leonard, 2004, Cancer Chemotherapy and Pharmacology.

A phase II study of carboplatin in advanced or metastatic stomach cancer.

F. Cavalli, M. van Glabbeke, S. Kaye, 1987, European journal of cancer & clinical oncology.

The interface between medical oncology and supportive and palliative cancer care.

M. Fallon, J. Smyth, D. Storey, 2011, Seminars in oncology.

Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report.

M. Borner, J. Smyth, P. Fumoleau, 2001, European journal of cancer.

Advanced gastric cancer: Experience in Scotland using 5‐fluorouracil, adriamycin and mitomycin‐C

P. Boyle, C. McArdle, K. Calman, 1984, The British journal of surgery.

Metabolism of the anticancer peptide: H-Arg-d-Trp-NmePhe-d-Trp-Leu-Met-NH2

J. Smyth, S. Langdon, E. Rozengurt, 1995, Peptides.

Mucinous Endometrial Carcinoma in a Patient with Previous Ovarian Endometrioid Adenocarcinoma Presenting Some 18 Years after Initial Bilateral Ovariectomy: A Case Report

J. Smyth, G. Beattie, M. Cornbleet, 1991, Scottish Medical Journal.

Immunopathological effects of intravesical BCG therapy.

J. Smyth, S. Prescott, K. James, 1989, Progress in clinical and biological research.

Randomized phase II trial of iproplatin and carboplatin in advanced breast cancer. The EORTC Early Clinical Trials Group and the EORTC Data Center.

S. Kaye, J. Smyth, S. Gundersen, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Expression of erbB-4/HER-4 growth factor receptor isoforms in ovarian cancer.

J. Smyth, W. Gullick, S. Langdon, 2001, Cancer research.

Metabolism of the broad-spectrum neuropeptide growth factor antagonist: [D-Arg1, D-Phe5, D-Trp7,9, Leu11]-substance P.

J. Smyth, S. Langdon, E. Rozengurt, 1996, British Journal of Cancer.

Rapid and selective isolation of radiolabelled inositol phosphates from cancer cells using solid-phase extraction.

J. Cummings, J. Smyth, L. Anderson, 1992, Journal of Chromatography A.

A phase II study of sulofenur (LY186641) in gastric cancer

J. Smyth, R. Coleman, J. Walling, 1992, Anti-cancer drugs.

Preclinical studies on the broad-spectrum neuropeptide growth factor antagonist G.

J. Smyth, S. Langdon, David Ackley Jones, 1997, General pharmacology.

Characterization of the deamidase enzyme responsible for the metabolism of the anticancer peptide: H-Arg-D-Trp-NmePhe-D-Trp-Leu-Met-NH2.

J. Smyth, S. Langdon, David Ackley Jones, 1995, Biochemical pharmacology.

Pharmacokinetics, metabolism, tissue and tumour distribution of the neuropeptide growth factor antagonist [Arg6, D-Trp7,9, NmePhe8]- substance P(6-11) in nude mice bearing the H69 small-cell lung cancer xenograft.

J. Smyth, S. Langdon, E. Rozengurt, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Pharmacokinetics, Bioavailability, Metabolism, Tissue Distribution and Urinary Excretion of γ‐L‐Glutamyl‐L‐dopa in the Rat

J. Cummings, J. Smyth, L. M. Matheson, 1990, The Journal of pharmacy and pharmacology.

Guidelines for regional genetic centres on the implementation of genetic services for the breast, ovarian and colorectal cancer families in Scotland

H. Campbell, A. Thompson, R. Black, 2000 .

MOBILISATION OF LEAD BY CISPLATIN

P. Tothill, J. Smyth, L. M. Matheson, 1989, The Lancet.

Phase II study of 9-hydroxy-2-methyl-ellipticinium acetate (ellipticinium) in patients with advanced carcinoma of the lung

O. Dalesio, J. Smyth, A. Kirkpatrick, 1989 .

LYMPHOMA AFTER S.L.E.

J. Smyth, B. Fitzharris, A. Barrett, 1978, The Lancet.

Phase II Evaluation in Patients with Non-Hodgkin’s Lymphoma the Old World Experience — An Interim Report

D. Crowther, J. Smyth, H. Høst, 1985 .

Adult neuroblastoma report of three cases and review of the literature

J. Carmichael, J. Smyth, M. Cornbleet, 1986, Cancer.

Mechanism of Action of Anti-Cancer Drugs

K. Calman, M. Tattersall, J. Smyth, 1980 .

A phase II study of carboplatin in metastatic transitional cell carcinoma of the bladder

P. Wilkinson, L. Freedman, D. Newling, 1987 .

Interferons Combined with Other Anti-Cancer Agents — Studies in Experimental Systems

F. Balkwill, J. Smyth, R. Fergusson, 1987 .

Diazepam ablates the constitutional side-effects of gamma interferon

J. Smyth, G. Beattie, 1988, Medical oncology and tumor pharmacotherapy.

Interferons in oncology: current status and future directions.

F. Cavalli, A. Kimchi, F. Balkwill, 1987, European journal of cancer & clinical oncology.

Rationale for drug combinations.

J. Smyth, 2003, European journal of cancer.

Phase I and pharmacokinetic study of ecteinascldin-743 (ET-743) given as a one hour infusion every 21 days

J. Beijnen, J. Smyth, C. Twelves, 1997 .

Phase II study of letrozole in estrogen receptor (ER) positive relapsed epithelial ovarian cancer (EOC).

H. Gabra, P. Vasey, J. Smyth, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Investigator-initiated trials of targeted oncology agents: why independent research is at risk?

A. Dalgleish, H. Zwierzina, J. Smyth, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

The regulation of growth and protein expression by estrogen in vitro: A study of 8 human ovarian carcinoma cell lines

J. Smyth, S. Langdon, W. Miller, 1994, The Journal of Steroid Biochemistry and Molecular Biology.

Growth of small cell lung cancer cells: stimulation by multiple neuropeptides and inhibition by broad spectrum antagonists in vitro and in vivo.

J. Smyth, S. Langdon, E. Rozengurt, 1992, Cancer research.

Broad spectrum neuropeptide antagonists inhibit the growth of small cell lung cancer in vivo.

J. Smyth, S. Langdon, E. Rozengurt, 1992, Cancer research.

Prognostic factors in advanced non-seminomatous germ-cell testicular tumours: results of a multicentre study

K. Sikora, A. Horwich, P. Wilkinson, 1985 .

Estrogen regulation of transforming growth factor-alpha in ovarian cancer.

J. Bartlett, J. Smyth, S. Langdon, 1998, The Journal of steroid biochemistry and molecular biology.

A phase II trial of TCNU in patients with squamous, adeno and large cell carcinoma of the lung.

H. Hansen, A. Pedersen, J. Smyth, 1989, European journal of cancer & clinical oncology.

Pharmacokinetics of tauromustine in cancer patients

H. Hansen, J. S. Macpherson, J. Smyth, 1989, Cancer Chemotherapy and Pharmacology.

Phase II study of TCNU in advanced breast cancer.

A. Howell, P. Dombernowsky, J. Smyth, 1988, European Journal of Cancer and Clinical Oncology.

Role of TGFα stimulation of the ERK, PI3 kinase and PLCγ pathways in ovarian cancer growth and migration

J. Smyth, S. Langdon, J. Sewell, 2005 .

Complications of Cancer Chemotherapy

K. Calman, M. Tattersall, J. Smyth, 1980 .

Phase IClinical and Pharmacokinetic Study of Plitidepsin as a 1-Hour Weekly Intravenous Infusion in Patientswith Advanced SolidTumors

J. Smyth, D. Jodrell, M. Garci, 2008 .

Chemotherapy of small cell lung cancer.

J. Smyth, J F Smyth, 1989, Chest.

Optimisation of a reversed-phase high-performance liquid chromatographic method for the determination of flavone acetic acid and its major human metabolites in plasma and urine.

S. Kaye, J. Cummings, J. Smyth, 1988, Journal of chromatography.

Method for the determination of γ-l-glutamyl-l-dihydroxyphenylalanine and its major metabolites l-dihydroxyphenylalanine, dopamine and 3,4-dihydroxyphenylacetic acid by high-performance liquid chromatography with electrochemical detection

J. Cummings, J. Smyth, L. M. Matheson, 1990 .

The tumor-promoting actions of TNF-alpha involve TNFR1 and IL-17 in ovarian cancer in mice and humans.

G. Kollias, T. Lawrence, P. Chakravarty, 2009, The Journal of clinical investigation.

The use of real-world data in cancer drug development.

E. Skovlund, J. Smyth, H. Leufkens, 2018, European journal of cancer.

Clinically relevant fatigue in recurrence-free prostate cancer survivors.

M. Sharpe, J. Smyth, D. McLaren, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

The anti-proliferative activity of interferon-gamma on ovarian cancer: in vitro and in vivo.

F. Balkwill, J. Smyth, L. Wall, 2003, Gynecologic oncology.

Small intestinal mucosal toxicity of cis-platinum--comparison of toxicity with platinum analogues and dexamethasone.

J. Smyth, S. Allan, 1986, British Journal of Cancer.